详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Research progress of astragaloside IV in treating acute kidney injury

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Nephrology, Health Science Center, South China Hospital, Shenzhen University, No.1, Fuxin Road, Longgang District, Shenzhen, People's Republic of China. [2]Guangdong Key Laboratory for Biomedical Measurements and Ultrasound, ImagingSchool of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China. [3]Department of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, Sichuan, China. [4]The Chinese University of Hong Kong, No. 2001, Longxiang Avenue, Shenzhen, Guangdong, China.

出处：

DOI：

ISSN：

关键词： Astragalus Astragaloside IV Acute kidney injury

摘要：

Acute kidney injury (AKI) is one of the most common clinical critical illnesses, with decreased glomerular filtration rate, retention of nitrogen products, water and electrolyte disorders, and acid-base imbalance as the main clinical manifestations. Presently, there is no effective treatment for acute kidney injury, but the main treatment is to cure the primary disease, remove risk factors, maintain acid-base and water-electrolyte balance, and undergo kidney replacement. However, the mortality rate is still high. Investigations and studies showed that the mortality rate of patients with acute kidney injury in the ICU is 5-80% [1]. In recent years, Chinese medicine has been widely used in acute kidney injury treatment due to its complete dialectical system and rich experience. Astragalus is a commonly used medicine in traditional Chinese medicine to treat acute kidney injury. Astragaloside IV is the main active component of traditional Chinese medicine, Astragalus membranaceus. This article summarizes the relevant studies on treating acute kidney injury with astragaloside IV.© 2024. The Author(s), under exclusive licence to Springer Nature B.V.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区泌尿学与肾脏学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区泌尿学与肾脏学

第一作者：

第一作者机构： [1]Department of Nephrology, Health Science Center, South China Hospital, Shenzhen University, No.1, Fuxin Road, Longgang District, Shenzhen, People's Republic of China. [2]Guangdong Key Laboratory for Biomedical Measurements and Ultrasound, ImagingSchool of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Investigation of the Metabolism of Astragaloside IV in a Puromycin-Damaged Rat Model by UPLC-Q-TOF-MS/MS Analysis [2]Predicting in-hospital outcomes of patients with acute kidney injury [3]Protective Mechanism of Cordyceps sinensis Treatment on Acute Kidney Injury-Induced Acute Lung Injury through AMPK/mTOR Signaling Pathway [4]Astragaloside IV alleviates E. coli-caused peritonitis via upregulation of neutrophil influx to the site of infection. [5]Detecting Neonatal Acute Kidney Injury by Serum Cystatin C [6]Incidence, Risk Factors and Outcome of Postoperative Acute Kidney Injury in China [7]JianPiYiShen formula prevents cisplatin-induced acute kidney injury in mice by improving necroptosis through MAPK pathway [8]Shenshuaifu Granule Attenuates Acute Kidney Injury by Inhibiting Ferroptosis Mediated by p53/ SLC7A11/GPX4 Pathway [9]Gastroprotective Effects of Astragaloside IV against Acute Gastric Lesion in Rats [10]Compatibility of Tanshinone IIA and Astragaloside IV in attenuating hypoxia-induced cardiomyocytes injury